Design Financial Statements From 2010 to 2026

DSGN Stock

USD 10.27 0.32 3.22%

Design Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Design Therapeutics' valuation are provided below:

Gross Profit

-57.9 M

Market Capitalization

585 M

Enterprise Value Revenue

11 K

Revenue

33 K

Earnings Share

(1.19)

We have found one hundred twenty available fundamental signals for Design Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to verify Design Therapeutics' prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 8th of February 2026, Market Cap is likely to drop to about 392 M. In addition to that, Enterprise Value is likely to drop to about 369.6 M

Check Design Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Design Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 719.7 K, Interest Expense of 5.7 M or Selling General Administrative of 13.3 M, as well as many indicators such as Price To Sales Ratio of 1.1 M, Dividend Yield of 0.0 or PTB Ratio of 1.36. Design financial statements analysis is a perfect complement when working with Design Therapeutics Valuation or Volatility modules.

Build AI portfolio with Design Stock

Check out the analysis of Design Therapeutics Correlation against competitors.

To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.

Design Therapeutics Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

240.2 M

289.9 M

108.3 M

Slightly volatile

Short and Long Term Debt Total

2.9 M

2.7 M

1.7 M

Slightly volatile

Other Current Liabilities

4.4 M

6.3 M

2.2 M

Slightly volatile

Total Current Liabilities

7.4 M

9.7 M

5.3 M

Slightly volatile

Other Liabilities

175.1 K

166.8 K

63.3 K

Slightly volatile

Current Deferred Revenue

160.8 K

180.9 K

197.5 K

Slightly volatile

Accounts Payable

2.3 M

2.5 M

2.3 M

Pretty Stable

Cash

19.3 M

20.3 M

24.2 M

Slightly volatile

Cash And Short Term Investments

234.3 M

282.3 M

105.6 M

Slightly volatile

Common Stock Total Equity

3.9 K

6.9 K

2.7 K

Slightly volatile

Common Stock Shares Outstanding

49.2 M

65.1 M

36.9 M

Slightly volatile

Liabilities And Stockholders Equity

240.2 M

289.9 M

108.3 M

Slightly volatile

Non Current Liabilities Total

1.3 M

1.4 M

3.4 M

Pretty Stable

Other Current Assets

1.4 M

1.5 M

629.2 K

Slightly volatile

Total Liabilities

12.8 M

9 M

8.9 M

Slightly volatile

Short and Long Term Debt

556 K

625.5 K

682.7 K

Slightly volatile

Total Current Assets

236.4 M

285.2 M

106.6 M

Slightly volatile

Capital Stock

4.8 K

6.9 K

2.7 K

Slightly volatile

Non Current Liabilities Other

3.7 M

3.5 M

1.2 M

Slightly volatile

Short Term Debt

734.8 K

920 K

690.5 K

Pretty Stable

Common Stock

4.8 K

6.9 K

2.7 K

Slightly volatile

Other Assets

0.86

0.9

191.2 K

Slightly volatile

Net Receivables

864.6 K

1.5 M

373.4 K

Slightly volatile

Deferred Long Term Liabilities

169.6 K

190.8 K

208.3 K

Slightly volatile

Property Plant Equipment

1.3 M

2.2 M

686 K

Slightly volatile

Capital Surpluse

479.2 M

507.6 M

439.4 M

Slightly volatile

Design Therapeutics Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Depreciation And Amortization

719.7 K

685.4 K

182.2 K

Slightly volatile

Selling General Administrative

13.3 M

20.7 M

6.9 M

Slightly volatile

Other Operating Expenses

46.7 M

71.7 M

22.9 M

Slightly volatile

Research Development

33.5 M

51 M

16.6 M

Slightly volatile

Cost Of Revenue

719.7 K

685.4 K

185.6 K

Slightly volatile

Total Operating Expenses

46.4 M

71.1 M

22.8 M

Slightly volatile

Non Operating Income Net Other

2.5 M

4.9 M

1.4 M

Slightly volatile

Net Interest Income

13.3 M

14.7 M

11.7 M

Slightly volatile

Interest Income

13.3 M

14.7 M

11.7 M

Slightly volatile

Design Therapeutics Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Begin Period Cash Flow

23.2 M

24.4 M

23.3 M

Slightly volatile

Capital Expenditures

587.4 K

391 K

286.3 K

Slightly volatile

Total Cash From Financing Activities

438.6 K

461.7 K

25.2 M

Pretty Stable

End Period Cash Flow

19.3 M

20.3 M

24.2 M

Slightly volatile

Change To Netincome

13.2 M

12.6 M

3.8 M

Slightly volatile

Sale Purchase Of Stock

361.6 K

548.5 K

256.4 K

Slightly volatile

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

1.1 M

1.2 M

1.3 M

Slightly volatile

EV To Sales

1.1 M

1.2 M

1.3 M

Slightly volatile

Payables Turnover

0.26

0.25

0.081

Slightly volatile

Sales General And Administrative To Revenue

1 K

1.2 K

1.3 K

Slightly volatile

Research And Ddevelopement To Revenue

1.6 K

1.8 K

1.9 K

Slightly volatile

Cash Per Share

3.34

3.9

1.8975

Slightly volatile

Days Payables Outstanding

1.5 K

322.6 K

Slightly volatile

Income Quality

0.6

0.78

0.3817

Slightly volatile

Current Ratio

23.8

26.38

13.4657

Slightly volatile

Capex Per Share

0.0066

0.0069

0.0062

Slightly volatile

Revenue Per Share

0.0

Slightly volatile

Interest Debt Per Share

0.0426

0.0371

0.0386

Slightly volatile

Debt To Assets

0.0101

0.0106

4.5466

Slightly volatile

Days Of Payables Outstanding

1.5 K

322.6 K

Slightly volatile

Ebt Per Ebit

1.03

0.91

1.0126

Slightly volatile

Quick Ratio

23.8

26.38

13.4657

Slightly volatile

Cash Ratio

2.91

3.07

4.1795

Pretty Stable

Free Cash Flow Operating Cash Flow Ratio

1.12

1.16

1.027

Slightly volatile

Debt Ratio

0.0101

0.0106

4.5466

Slightly volatile

Price Sales Ratio

1.1 M

1.2 M

1.3 M

Slightly volatile

Asset Turnover

0.0074

0.0083

0.0091

Slightly volatile

Design Therapeutics Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

392 M

401.5 M

513 M

Slightly volatile

Enterprise Value

369.6 M

378.3 M

490.6 M

Slightly volatile

Design Fundamental Market Drivers

Design Upcoming Events

	12th of March 2024 Upcoming Quarterly Report	View
	14th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	12th of March 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Design Therapeutics Financial Statements

Design Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Design Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Current Deferred Revenue	180.9 K	160.8 K
Cost Of Revenue	685.4 K	719.7 K
Sales General And Administrative To Revenue	1.2 K	1 K
Research And Ddevelopement To Revenue	1.8 K	1.6 K
Ebit Per Revenue	-2.1 K	-2.2 K

Pair Trading with Design Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Design Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Design Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Design Stock

0.78

ENGN

enGene Holdings Common

Pair Corr

Moving against Design Stock

0.78	GNLX	Genelux Common	Pair Corr
0.75	EVGN	Evogene	Pair Corr
0.73	EDIT	Editas Medicine	Pair Corr
0.7	QSI	QuantumSi	Pair Corr
0.69	LYRA	Lyra Therapeutics	Pair Corr

The ability to find closely correlated positions to Design Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Design Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Design Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Design Therapeutics to buy it.

The correlation of Design Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Design Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Design Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Design Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Design Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Design Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Design Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Design Therapeutics Stock:

How To Invest In Design

Details

Is Design Stock a good investment?

Details

What is Design Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Design Therapeutics Correlation against competitors.

To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.

You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Will Biotechnology sector continue expanding? Could Design diversify its offerings? Factors like these will boost the valuation of Design Therapeutics. Projected growth potential of Design fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Design Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Earnings Share

(1.19)

Revenue Per Share

0.001

Return On Assets

(0.20)

Return On Equity

(0.30)

Investors evaluate Design Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Design Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Design Therapeutics' market price to deviate significantly from intrinsic value.

It's important to distinguish between Design Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Design Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Design Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Design Financial Statements From 2010 to 2026

Design Therapeutics Balance Sheet

Design Therapeutics Income Statement

Design Therapeutics Cash Flow Statement

Financial Ratios

Design Therapeutics Valuation Data

Design Fundamental Market Drivers

Design Upcoming Events

About Design Therapeutics Financial Statements

Pair Trading with Design Therapeutics

Moving together with Design Stock

Moving against Design Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY